Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · OptimizeRx Corp (OPRX)

OptimizeRx shareholders approve 1M-share equity plan increase, reject evergreen provision

Neutral Impact 2 of 5 shareholder Written later

At the June 9, 2026 annual meeting, OptimizeRx shareholders approved Amendment No. 2, which adds 1,000,000 shares to the 2021 Equity Incentive Plan for a total of 5,450,000 shares. Shareholders did not approve a separate amendment that would have added an automatic annual increase to the plan's share pool, and they elected seven directors and ratified Grant Thornton LLP as auditor for fiscal 2026.

Key points

  • Equity Plan share reserve increased by 1,000,000 shares to 5,450,000: 11,541,123 votes for, 1,096,197 against, 16,476 abstaining.
  • Evergreen provision for automatic annual share increases was not approved: 5,627,324 votes for, 7,001,699 against, 24,773 abstaining.
  • All seven director nominees were elected to terms ending at the next annual meeting, with votes for ranging from 8,092,151 to 12,160,558.
  • Grant Thornton LLP was ratified as independent registered public accounting firm for fiscal year ending December 31, 2026: 15,750,329 votes for, 27,585 against.

The filing

CompanyOptimizeRx Corp (OPRX)
Form8-K, current report
Filed with the SECJun 12, 2026, 4:10 PM ET
Accession number0001213900-26-068272

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.